Royalty Pharma Reports First Quarter 2023 Results
Retrieved on:
星期二, 五月 9, 2023
Asthma, Share repurchase, BioCryst Pharmaceuticals, Cohort, DPP, GAAP, Letermovir, Acquisition, Patient, Risk, Cystic fibrosis, Ageing, Ionis Pharmaceuticals, Psychiatry, Vertex, Cardiovascular disease, Aplastic anemia, Gilead, Bronchoconstriction, Growth, FDA, Calcitonin, Net, Pressure, Migraine, Psychosis, Schizophrenia, HER2, Cabozantinib, Leuprorelin, Psoriasis, Cytokinetics, Astellas Pharma, Progression-free survival, RCC, LVEF, Calendar, Exelixis, COVID, AstraZeneca, Sale, EBITDA, HCM, PureTech Health, Breast cancer, Generic drug, Bank, Video game, Pharmaceutical industry, Music, Bookkeeping, Ionis, Natalizumab, Sacituzumab govitecan, Ibrutinib, Salbutamol/budesonide, Elexacaftor/tezacaftor/ivacaftor, KarXT, Adjustment, Pfizer
As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.
Key Points:
- As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.
- Drivers of royalty receipts in the first quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
- Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
- Royalty Pharma will also receive 25% of Ionis’ mid-teens to low-20% royalty on net sales of pelacarsen, resulting in a mid-single digit royalty to Royalty Pharma.